Emergent BioSolutions | EBS - Market Capitalization


Emergent BioSolutions reported $391.5M in Market Capitalization this July of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
Akebia Therapeutics USD 427M 297M Dec/2025
ALKERMES USD 5.88B 1.26B Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Amarin USD 290M 51M Dec/2025
ANI Pharmaceuticals USD 1.75B 24M Mar/2026
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
Coherus Biosciences USD 172M 19M Dec/2025
Emergent BioSolutions USD 125M 51M Dec/2023
Exelixis USD 10.89B 857M Mar/2026
Glaxosmithkline GBP 108.55B 736M Jul/2026
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
Lexicon Pharmaceuticals USD 418M 73M Dec/2025
Lonza CHF 39.68B 980.61M Jun/2025
Merck USD 297.1B 35.84B Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Nektar Therapeutics USD 12.82B 11.96B Jul/2026
Neurocrine Biosciences USD 13.25B 890M Mar/2026
Pacira USD 915M 149M Mar/2026
Pfizer USD 153.81B 12.24B Mar/2026
PTC Therapeutics USD 5.64B 460M Mar/2026
Sanofi EUR 100.27B 605.48M Mar/2026
Sarepta Therapeutics USD 2.28B 30M Mar/2026
United Therapeutics USD 25.19B 4.21B Mar/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024